Abstract: Example shoe manufacturing methods and related computer readable medium for implementing a portion of said manufacturing methods are disclosed herein. In some examples, the method includes placing an upper member about an upper portion of a last, wherein the last is a form for the shoe. In addition, the method includes producing a lasting based on data relating to a foot of a user, and attaching the lasting to the upper member, wherein the lasting extends over a lower portion of the last. Further, the method includes molding a sole onto the lasting and the upper member, and removing the last from the upper member.

Abstract: An example physical last includes a body having a bottom region. The physical last also includes a fitting attachable to the bottom region to define a component of a shoe. The fitting is manufactured based on three dimensional (3D) scan data of a foot of a customer and pressure data associated with the foot of the customer.

Abstract: Invented are non-peptide TPO mimetics. Also invented is a method of treating thrombocytopenia, in a mammal, including a human, in need thereof which comprises administering to such mammal an effective amount of a selected substituted thiosemicarbazone derivative.

Abstract: Invented are non-peptide TPO mimetics. also invented is a method of treating thrombocytopenia, in a mammal, including a human, in need thereof which comprises administering to such mammal an effective amount of a selected substituted thiosemicarbazone derivative.

Abstract: Non-peptide TPO mimetics are disclosed, as well as a method of treating thrombocytopenia, in a mammal, including a human, in need thereof, which comprises administering to such mammal an effective amount of a selected hydroxy-1-azo-naphthalene derivative.

Abstract: Invented are metal chelated dimeric cell-surface receptor ligands, pharmaceutical compositions containing these compounds, and methods of using these compounds as agonist of dimeric cell-surface receptors. Also invented are novel processes used in preparing these compounds. Also invented are novel receptor binding moieties of the invented metal chelated cell-surface receptor ligands.

Abstract: Dimeric cell-surface receptors in a subject are agonized by administering a metal chelated dimeric cell-surface receptor ligand formed by chelating a receptor binding moiety with a metal ion such as zinc, or by co-administering the receptor binding moiety and the metal ion. The binding moiety is a small organic molecule having a molecular weight of from about 100 to about 850, and metal chelation may form a symmetrical multimer such as a dimer of the receptor binding moiety. An example is bis{2,5-bis[2-benzimidazolylimino]-3a,6a-bis(2-pyridyl)-1,2,3,3a,4,5,6,6a-octahydroimidazo[4,5-d]imidazole-N,N′}-zinc(II). Dimeric cell surface receptors include granulocyte colony-stimulating factor, erythropoeitin receptor, macrophage-colony-stimulating factor, growth hormone receptor, thrombopoietin receptor, interferon alpha receptor, interferon beta receptor, tyrosine kinase receptor, insulin receptor and leptin receptor.

Abstract: Invented are zinc chelated G-CSF receptor ligands, pharmaceutical compositions containing these compounds, and methods of using these compounds as agonist of the G-CSF receptor. Also invented are novel processes used in preparing these compounds. Also invented are novel G-CSF receptor binding moieties of the invented zinc chelated G-CSF receptor ligands.

Abstract: Surface relief of a finger is read using an optical-fiber prism unit, with fiber terminations at one end to contact the surface, and at the other for light passages along fibers from the first. Light enters where NA<0.5 and fiber diameter is constant with longitudinal position. The device is in a 1.4-2 L case, with a battery or power unit, converter to form a corresponding data array for verifying, digital signal processor to do the verifying, and output to indicate or implement a decision. The optical fiber prism unit has a substantially circular cylindrical wall defining a longitudinal axis, fused optical fibers parallel to the longitudinal axis, a traverser face for output of a skin pattern image from the prism and a generally elliptical angled face for contacting such a skin pattern.

Abstract: This invention relates to the isolation and cloning of the promoter and other control regions of a human ob gene. It provides a method for identifying and screening for agents useful for the treatment of diseases and pathological conditions affected by the level of expression of an ob gene. These agents interact directly or indirectly with the promoter or other control regions of the ob gene. A PPAR.gamma. agonist, BRL49653, has been identified to be useful in treating anorexia, cachexia, and other diseases characterized by insufficient food intake or body weight loss. Modulators of ob gene expression may be used to treat other diseases such as obesity, diabetes, hypertension, cardiovascular diseases and infertility.

Abstract: Surface relief of a finger etc. is read using an optical-fiber prism unit, with fiber terminations at one end to contact the surface, and at the other for light passage along fibers from the first. Light enters where NA<0.5 and fiber diameter is constant with longitudinal position. The device is in a 1.4-2 L case, with a battery or power input, converter to form a corresponding data array for verifying, digital signal processor to do the verifying, and output to indicate or implement a decision. A video controller (with custom-programmed logic circuit) operates the sensors to develop the data array; an ADC digitizes the array; memory holds an authorized-user skin-pattern template, firmware for the processor, and data used in verifying; an output register holds the decision signal--all on a control, address, and data bus. High-power, radiative elements and a fast high-impedance data reader are on a common board in an isolating layout.